Group items matching

in title, tags, annotations or url

To support future neurosurgical educators in pursuit of new training modalities, including the development of neurosurgical simulators, novel web-based technologies, or other surgical training innovations.

The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. Proposals must have a well-defined plan for moving toward clinical utility for Parkinson's disease (PD) patients. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson's disease therapeutic and intervention development along the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).

The Chan Zuckerberg Initiative is inviting applications to join the CZI Neurodegeneration Challenge Network. The goal of this interdisciplinary collaborative initiative is to bring together forward-thinking scientists to work on the challenge of neurodegenerative disorders, with a focus on basic mechanisms in the context of human disease biology.

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward breakthroughs for Parkinson's patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work. In addition to funding, awardees benefit from working with our internal research staff and broad network of scientific and industry advisors. Targeted Funding Opportunities | Application Deadline: May 31, 2018: 1. Alpha-synuclein Biology and Therapies 2. GBA Biology and Therapies 3. Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids 4. Non-Pharmacological Interventions for Gait and Balance Disturbances

NYSCF is soliciting applications from early career investigators for Innovator awards in neuroscience. The goal of this initiative is to foster truly bold, innovative scientists with the potential to transform the field of neuroscience. Applicants are encouraged in the fundamental areas of developmental, cellular, cognitive, and translational neuroscience, broadly interpreted. Applicants need not be working in areas related to stem cells. The award provides $1.5M USD over 5 years and is open to researchers based at both national and international accredited academic and nonprofit research institutions. To be eligible, candidates must: - Have completed one or more of the following degrees: MD, PhD, DPhil - Be within 5 years of starting a faculty (professorship) or comparable position on June 1, 2018 - Have demonstrated ability to independently supervise staff and research - Have a publication record containing articles that are innovative and high impact

The Michael J. Fox Foundation has issued a request for proposals to investigate environmental factors that increase Risk for Parkinson's disease. While some evidence links environmental factors with increased risk of PD, according to the foundation much remains unknown regarding the specific environmental risks, their role in disease, and the quantification of their contributions. A better understanding of environmental risk factors for PD could lead to efforts to reduce or prevent such exposures.

The goal of the Pilot Award is to provide early support for exploratory ideas, particularly those with novel hypotheses. Appropriate projects for this mechanism include those considered higher risk but with the potential for transformative results. To get a better understanding of SFARI's different RFAs and whether the Pilot Award may be the best mechanism to support your project, please read our blog post "SFARI RFA reboot: Why, what and how". In particular, we encourage applications that propose research to link genetic or other ASD risk factors to molecular, cellular, circuit or behavioral mechanisms of ASD. Please read more about SFARI's scientific perspectives here. We also strongly advise applicants to familiarize themselves with the current projects and other resources that SFARI supports and to think about how their proposals might complement existing efforts.

Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies. The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects. Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

The Taking Flight Award seeks to promote the careers of young epilepsy investigators, enabling them to develop a research focus independent of their mentor(s). In 2018, CURE will issue one request for proposals for the Taking Flight Award. Please refer to the LOI guidelines for an overview of CURE's 2018 priority areas, application instructions and FAQs. Eligibility You must fall into one of the following categories to be eligible for the Taking Flight Award: A senior postdoctoral fellow who has a minimum of 3 years postdoctoral experience A clinical fellow who is a Neurology Resident in his/her Neurology training and considering Epilepsy Fellowships Newly appointed faculty within one year of having completed postdoctoral training

The Cognitive Neuroscience Program seeks highly innovative and interdisciplinary proposals aimed at advancing a rigorous understanding of how the human brain supports thought, perception, affect, action, social processes, and other aspects of cognition and behavior, including how such processes develop and change in the brain and through time.

The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports: * Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) * Comparative Effectiveness Research: Methods may include randomized trials or epidemiology. * Studies of Cognitive Decline and Cognitive Reserve: Methods may include epidemiology or clinical trials. Current target areas of interest include: - Epigenetics - Inflammation - Mitochondria & metabolic function - Neuroprotection - Proteostasis - Synaptic activity and neurotransmitters - Vascular function - Other aging targets (e.g. senescent cells) - Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk   

The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Specifically, this RFP focuses on: - developing novel PET ligands for clinical use - supporting novel CSF biomarkers - validating established MRI approaches in larger cohorts Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: - Neuronal loss - Vascular injury and blood-brain barrier integrity - Mitochondria and metabolic function - Protein misfolding/proteostasis - Oxidative stress - White matter changes - Other novel targets supported by compelling biological rationale and connection to disease The ADDF has limited interest in CSF measures of amyloid and tau.

Applications should focus on studies that achieve one or more of the following: - In vivo imaging of brain neurofilaments of 4R tau and alpha-synuclein pathology that could be useful as biomarkers of the presence of disease and disease progression and as pharmacodynamic tools for drug development for tauopathies or synucleinopathies - Structure- and ligand-based drug design approaches that use state-of-art computational methods such as the high resolution Cryo-EM structures of disease-relevant tau and alpha-synuclein fibrils and existing Structure Activity Relationship (SAR) on known tau PET ligands or alpha-synuclein PET ligands that are in development We are especially interested in projects to develop alpha-synuclein and tau tracers in parallel.

Applications should focus on studies that achieve one or more of the following for Parkinson's: - Develop or validate promising biomarkers of disease - Develop or validate prodromal biomarkers - Develop or validate biomarkers of phenoconversion - Develop or validate specific molecular biomarker assays - Analyze and derive candidate biomarkers from existing biological datasets - Develop and support remote assessment strategies that could complement in clinic assessments